| 摘要 |
The use of pteridines and/or their biochemical precursors or of a xanthine oxidase inhibitor for the treament of genetically induced degenerative diseases of the retina (especially retinopathia pigmentosa) is new. Pref. pteridines are monapterin, sepiapterin and the preferred xanthine oxidase inhibitor is allopurinol. Suitable formulations include topical eye drops (solutions, suspensions, emulsions or ointment) and ocular inserts (pref. delayed release).
|
